Pharmacologic treatments for co-occurring substance use disorders in patients with schizophrenia: A research review

Journal of Dual Diagnosis

Volumn 1, Issue 2, 2005, Pages 41-55

  Brunette, Mary F ^a,c   Noordsy, Douglas L ^a   Buckley, Peter F ^b   Green, Alan I ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c DARTMOUTH PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Schizophrenia; Substance abuse; Treatment medications

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA 2 ADRENERGIC RECEPTOR; AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BUPRENORPHINE; CLOZAPINE; DESIPRAMINE; DISULFIRAM; DOPAMINE; DOPAMINE 2 RECEPTOR; GABAPENTIN; IMIPRAMINE; METHADONE; MOOD STABILIZER; NALTREXONE; NORADRENALIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROIC ACID;

ADDICTION; ALCOHOL ABUSE; ALCOHOLISM; BIPOLAR DISORDER; CANNABIS ADDICTION; COCAINE DEPENDENCE; CRIMINAL BEHAVIOR; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG EFFICACY; FAMILY HISTORY; GABAERGIC TRANSMISSION; HUMAN; INFECTION RISK; LIVER TOXICITY; OPIATE ADDICTION; PATIENT COMPLIANCE; PSYCHOSIS; RECEPTOR BLOCKING; RELAPSE; REMISSION; REVIEW; REWARD; SCHIZOPHRENIA; SELF MEDICATION; SIDE EFFECT; SIGNAL DETECTION; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; WEIGHT GAIN;

EID: 22144474213     PISSN: 15504263     EISSN: 15504271     Source Type: Journal    
DOI: 10.1300/J374v01n02_04     Document Type: Review

References (108)

1. Kendler KS, Gallagher TJ, Abelson JM et al.: Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: The national comorbidity survey. Arch Gen Psychiatry 1996;53(11):1022-1031.
2. Regier DA, Farmer ME, Rae DS et al.: Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990;264:2511-2518.
3. Drake RE, Mueser KT: Alcohol-use disorder and severe mental illness. Alcohol Health Res World 1996;20:87-93.
4. Mueser KT, Yarnold PR, Levinson DF et al.: Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophr Bull 1990;16:31-56.
5. Selzer JA, Lieberman JA: Schizophrenia and substance abuse. Psychiatr Clin North Am 1993; 16:401-412.
6. Rolfe TJ, McGory P, Cooks J et al.: Cannabis use in first episode psychosis: Incidence and short-term outcome. Schizophr Res 1999;36:313.
7. Dalack GW, Healy DJ, Meador-Woodruff JH: Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings. Am J Psychiatry 1998;155: 1490-1501.
8. Hughes JR, Hatsukami DK, Mitchell JE et al.: Prevalence of smoking among schizophrenic outpatients. Am J Psychiatry 1986;143:993-997.
9. Drake RE, Wallach MA: Moderate drinking among people with severe mental illness. Hosp Community Psychiatry 1993;44:780-782.
10. Owen RR, Fischer EP, Booth BM et al.: Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996;47(8):853-8.
11. Swofford CD, Kasckow JW, Scheller-Gilkey G, et al.: Substance use: A powerful predictor of relapse in schizophrenia. Schizophr Res 1996;20:145-151.
12. Haywood TW, Kravitz HM, Grossman LS et al.: Predicting the revolving door phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995;152:856-861.
13. Swartz MS, Swanson JW, Hiday VA et al.: Violence and mental illness: The effects of substance abuse and nonadherence to medication. Am J Psychiatry 1998; 155:226-231.
14. Goodman LA, Rosenberg SD, Mueser KT et al.: Physical and sexual assault history in women with serious mental illness: Prevalence, correlates, treatment, and future research directions. Schizophr Bull 1997;23(4):685-96.
15. Neria Y, Bromet EJ, Sievers S et al.: Trauma exposure and posttraumatic stress disorder in psychosis: Findings from a first-admission cohort. J Consult Clin Psychol 2002;70(1):246-251.
16. Rosenberg SD, Goodman LA, Osher FC et al.: Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 2001; 91:31-37.
17. Abram KM, Teplin LA: Co-occurring disorders among mentally ill jail detainees. Am Psychol 1991;46:1036-1044.
18. Hurlburt MS, Hough RL, Wood PA: Effects of substance abuse on housing stability of homeless mentally ill persons in supported housing. Psychiatr Serv 1996;47:731-736.
19. Addington J: Early intervention strategies for co-morbid cannabis use and psychosis. Inaugural International Cannabis and Psychosis Conference. Melbourne, 1999.
20. Green AI, Tohen M, Hamer RM et al.: First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol. Schizophr Res 2004;66(2-3):125-135.
21. Deganhardt L, Hall W, Lynskey M: Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 2003;71:37-48.
22. Lieberman J, Kane J, Alvir J: Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987;91(4):415-433.
23. Drake RE, Osher FC, Wallach MA: Alcohol use and abuse in schizophrenia: A prospective community study. J Nerv Ment Dis 1989;177:408-414.
24. Treffen DA: Marijuana use in schizophrenia: A clear hazard. Am J Psychiatry 1978;135(10):1213-1215.
25. Khantzian EJ: The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harv Rev Psychiatry January/February: 1997; 231-244.
26. Siris S: Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull 1990;16:111-122.
27. Addington J, Addington D: Effect of substance misuse in early psychosis. Br J Psychiatry Suppl 1998;172(33):134-6.
28. Buckley P, Thompson P, Way L et al.: Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy. Am J Psychiatry 1994;151:385-389.
29. Glynn SH, Sussman S: Why patients smoke. Hosp Community Psychiatry 1990;41:1027-1028.
30. Kavanagh DJ, Waghorn G, Jenner L et al.: Demographic and clinical correlates of comorbid substance use disorders in psychosis: Multivariate analyses from an epidemiologic sample. Schizophr Res 2004;66:115-124.
31. Lysaker PH, Bell MD, Beam-Goulet J et al.: Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J Nerv Ment Dis 1994;182:109-112.
32. Yang YK, Nelson L, Kamaraju L et al.: Nicotine decreases bradykinesia-rigidity in Haloperidol-treated patients with schizophrenia. Neuropsychopharmacology 2002;27:684-686.
33. Brunette M, Mueser KT, Drake RE et al.: Relationships between symptoms of schizophrenia and substance abuse. J Nerv Ment Dis 1997;185:13-20.
34. Hamera E, Schneider JK, Stanley S: Alcohol, cannabis, nicotine, and caffeine use and symptoms distress in schizophrenia. J Nerv Ment Dis 1995;183:559-565.
35. Buchanan RW, Strauss ME, Breier A et al.: Attentional impairments in deficit and nondeficit forms of schizophrenia. Am J Psychiatry 1997;154:363-370.
36. Soni S, Brownlee M: Alcohol abuse in chronic schizophrenics: Implications for management in the community. Acta Psychiatr Scand 1991;84:272-276.
37. Green AI, Salomon M, Brenner M et al.: Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Target CNS Neurol Disord 2002; 1:129-139.
38. McEvoy J, Brown C: Smoking in first-episode patients with schizophrenia. Am J Psychiatry 1999;156(7):1120-1121.
39. Veen ND, Selten J, van der Tweel I et al.: Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004;161:501-506.
40. Noordsy DL, Drake RE, Biesanz JC et al.: Family history of alcoholism in schizophrenia. J Nerv Ment Dis 1994;182:651-655.
41. Bidaut-Russell M, Bradford SE, Smith EM: Prevalence of mental illnesses in adult offspring of alcoholic mothers. Drug Alcohol Depend 1994;35(2):81-90.
42. Jones P, Cannon M: The new epidemiology of schizophrenia. Psychiatr Clin North Am 1998;21(1): 1-25.
43. Kendler KS: A twin study of individuals with both schizophrenia and alcoholism. Br J Psychiatry 1985;147:48-53.
44. Kendler KS, Masterson CC, Davis KL: Psychiatric illness in first-degree relatives of patients with paranoid psychosis, schizophrenia and medical illness. Br J Psychiatry 1985;147:524-31.
45. Kendler KS, O'Neill FA, Burke J et al.: Irish study of high-density schizophrenia families: Field methods and power to detect linkage. AACN Clin Issues 1996; 67:179-190.
46. Kendler KS, Karkowski-Shuman L, Walsh D: The risk for psychiatric illness in siblings of schizophrenics: The impact of psychotic and non-psychotic affective illness and alcoholism in parents. Acta Psychiatr Scand 1996;94:49-55.
47. Green AI, Zimmet SV, Strous RD et al.: Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry 1999;6:287-296.
48. Stone WS, Faraone SV, Seidman LJ et al.: Concurrent validation of schizaotaxia: A pilot study. Biol Psychiatry 2001;50:434-440.
49. Chambers RA, Self DW: Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: An animal model of dual diagnosis schizophrenia. Neuropsychopharmacology 2002;2:889-905.
50. Chambers AR, Krystal JH, Self DW: A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001;50:71-83.
51. Fadda F, Mosca E, Colombo G, et al.: Effects of spontaneous ingestion of ethanol on brain dopamine metabolism. Life Sci 1989;44:281-287.
52. Goeders NE, Smith JE: Reinforcing properties of cocaine in the medial prefrontal cortex: Primary action on presynaptic dopaminergic terminals. Pharmacol Biochem Behav 1986;25:191-199.
53. Dervaux A, Bayle F, Laqueille X et al.: Is substance abuse in schizophrenia related to impulsivity, sensation seeking, or anhedonia? Am J Psychiatry 2001; 158(3):492-494.
54. Drake RE, Mueser KT, Brunette MF et al.: A review of treatment for clients with severe mental illness and co-occurring substance use disorders. Psychosoc Rehab J, 2004
55. Barrowclough C, Haddock G, Tarrier N, et al.: Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 2001;158:1706-1713.
56. Blankertz LE, Cnaan RA: Assessing the impact of two residential programs for dually diagnosed homeless individuals. Soc Serv Rev 1994;68:536-560.
57. Drake RE, McHugo GJ, Clark RE et al.: Assertive community treatment for patients with co-occurring severe mental illness and substance use disorder: A clinical trial. Am J Orthopsychiatry 1998;68:201-215.
58. Brunette MF, Drake RE, Lynde D et al.: Toolkit for integrated dual disorders treatment, Substance Abuse and Mental Health Services Administration, 2002.
59. Mueser KT, Noordsy DL, Drake RE et al.: Integrated Treatment for Dual Disorders: A Guide to Effective Practice. New York, Guilford Publications, 2003.
60. Krystal JH, D'Souza DC, Madonick S et al.: Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr Res 1999; 35:35-49.
61. Noordsy DL, Green AI: Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Curr Psychiatry Rep 2003;5(5):340-6.
62. Wilkins JN: Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull 1997;23:215-228.
63. Noordsy DL, Torrey WC, Mueser KT et al.: Recovery from severe mental illness: An intrapersonal and functional outcome definition. Int Rev Psychiatry 2002; 14:318-326.
64. Salyers MP, Mueser KT: Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res 2001;48:109-123.
65. McEvoy JP, Freudenreich O, Levin E et al.: Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl) 1995;119:124-126.
66. Buckley P, McCarthy M, Chapman P et al.: Clozapine treatment of comorbid substance abuse in patients with schizophrenia. Schizophr Res 1999;36:272.
67. Drake RE, Xie H, McHugo GJ et al.: The effects of clozapine on alcohol and drug use disorders among schizophrenic patients. Schizophr Bull 2000;26:441-449.
68. Green AI, Burgess ES, Zimmet SV et al.: Alcohol and cannabis use in schizophrenia: Effects of clozapine and risperidone. Schizophr Res 2003;60:81-85.
69. Lee ML: Clozapine and substance abuse in patients with schizophrenia. Can J Psychiatry 1998;45:855-856.
70. Zimmet SV, Strous RD, Burgess ES et al: Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: A retrospective survey. J Clin Psychopharmacol 2000;20:94-98.
71. George TP, Sernyak MJ, Ziedonis D et al.: Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1996;57:4-11.
72. McEvoy JP, Freudenreich O, McGee M et al.: Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 1995;37:550-552.
73. McEvoy J, Freudenreich O, McGee M et al.: Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 1999;46:125-129.
74. Albanese MJ: Risperidone in substance abusers with bipolar disorder. 39th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, 2000.
75. Smelson D, Losonczy M, Davis CW et al.: Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 2002;47(7):671-675.
76. Littrell KH, Petty RG, Hilligoss N et al.: Olanzapine treatment for patients with schizophrenia and substance abuse. J Sbst Abuse Treat 2001;21:217-221.
77. Noordsy DL, O'Keefe CD, Mueser KT et al.: Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv 2001;52:501-507.
78. Brown ES, Nejtek VA, Perantie DC: Neuroleptics and quetiapine in psychiatric illness with comorbid stimulant abuse. 57th Annual Convention of the Society of Biological Psychiatry. Philadelphia, Pennsylvania, 2002.
79. George TP, Ziedonis DM, Feingold A et al.: Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000;157:1835-1842.
80. Brady KT, Myrick H, Henderson S: Divalproex in the prevention of relapse to alcohol use. Drug Alcohol Depend 2002;67:323-330.
81. Myrick H, Henderson S, Brady KT et al.: Gabapentin in the treatment of cocaine dependence: A case series. J Clin Psychiatry 2001;1:19-23.
82. Casey DE, Daniel DG, Wassef AA et al.: Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003;28:182-192.
83. Citrome L: Schizophrenia and valproate. Psychopharmacol Bull 2003;37(suppl 2):74-88.
84. Hertzman M: Divalproex sodium to treat concomitant abuse and mood disorders. J Subst Abuse Treat 2002;18:371-372.
85. Brady KT, Sonne SC, RA: Valproate in the treatment of acute bipolar affective episodes by substance abuse: A pilot study. J Clin Psychiatry 1995;56:118-121.
86. Jablonowski K, Margolese HC, Chouinard G: Gabapentin-induced paradoxidal exacerbation of psychosis in a patient with schizophrenia. Can J Psychiatry 2002;47:975-976.
87. Petroff OA, Hyder F, Rothman DL et al.: Topiramate rapidly raises brain GABA in epilepsy patients. Epiloepsia 2001;42(4):543-548.
88. Johnson BA, Ait-Daoud N, Bowden CL: Oral topiramate for treatment of alcohol dependence: A randomized controlled trial. The Lancet 2003;361:1677-1685.
89. Millson RC, Owen JA, Lorberg GW et al.: Topiramate for refractory schizophrenia. Am J Psychiatry 2002;159:675.
90. Drapalski AL, Rosse RB, Peebles RR et al.: Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clinical Neuropsychopharmacology 2001;24(5):290-294.
91. Evins AE, Mayes VK, Rigottie NA et al.: A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 2001;3:397-403.
92. George TP, Vessicchio JC, Termine A et al.: A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 2002;52:53-61.
93. Weiner E, Ball MP, Summerfelt A et al.: Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia. Am J Psychiatry 2001;158:635-637.
94. Siris SG, Mason SE, Bennanzohn PC et al: Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients. Psychopharmacol Bull 1993;29:127-133.
95. Ziedonis D, Richardson T, Lee E et al.: Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull 1992;28:309-314.
96. Clark RE, Xie H, Brunette M: Benzodiazepine prescription practices and substance abuse in persons with schizophrenia. J Clin Psychiatry, 2004.
97. Brunette M, Noordsy DL, Xie H et al.: Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv 2003;54(10):1395-1401.
98. Kofoed LL, Kania J, Walsh T et al.: Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiatry 1986;143:867-872.
99. Kingsbury SJ, Salzman C: Disulfiram in the treatment of alcoholic patients with schizophrenia. Hosp Community Psychiatry 1990;41:133-134.
100. Mueser KT, Noordsy DL, Fox M et al.: Disulfiram treatment for alcoholism in severe mental illness. Am J Addict in press, 2003.
101. Dougherty RJ: Naltrexone in the treatment of alcohol dependent dual diagnosed patients. J Addict Dis 1997;16:107.
102. Maxwell S, Shinderman MS: Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. J Addict Dis 2000;19(3):61-9.
103. Maxwell S, Shinderman MS: Naltrexone in the treatment of dually diagnosed patients. J Addict Dis 1997;16:125.
104. Petrakis IL, O'Malley SS, Rounsaville B et al.: Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 2004;172:291-297.
105. O'Malley SS, Jaffe AJ, Chang G et al.: Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Arch Gen Psychiatry 1992;49:881-887.
106. Volpicelli JR, Alterman AI, Hayashida M et al.: Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876-887.
107. Mattick R, Breen C, Kimber J et al.: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. The Cochrane Database of Systematic Reviews 2, 2004.
108. Miotto P, Preti A, Frezza M: Heroin and schizophrenia: Subjective responses to abused drugs in dually diagnosed patients. J Clin Psychopharmacol 2001; 21(1):111-113.